ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
LAVA Therapeutics NV

LAVA Therapeutics NV (LVTX)

1.39
-0.05
( -3.47% )
Updated: 09:54:14

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
1.39
Bid
1.38
Ask
1.40
Volume
19,028
1.39 Day's Range 1.4207
0.8502 52 Week Range 4.21
Market Cap
Previous Close
1.44
Open
1.41
Last Trade
1
@
1.39
Last Trade Time
09:54:43
Financial Volume
US$ 26,700
VWAP
1.4032
Average Volume (3m)
496,203
Shares Outstanding
26,289,087
Dividend Yield
-
PE Ratio
-0.88
Earnings Per Share (EPS)
-1.6
Revenue
6.77M
Net Profit
-41.97M

About LAVA Therapeutics NV

LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells. LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Utrecht, Utrecht, Nld
Founded
-
LAVA Therapeutics NV is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LVTX. The last closing price for LAVA Therapeutics NV was US$1.44. Over the last year, LAVA Therapeutics NV shares have traded in a share price range of US$ 0.8502 to US$ 4.21.

LAVA Therapeutics NV currently has 26,289,087 shares outstanding. The market capitalization of LAVA Therapeutics NV is US$37.86 million. LAVA Therapeutics NV has a price to earnings ratio (PE ratio) of -0.88.

LVTX Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.086.106870229011.311.511.251619681.36058591CS
40.4344.79166666670.961.510.850212284181.33511875CS
120.3229.90654205611.071.510.85024962031.29233311CS
26-0.31-18.23529411761.72.0930.85022596301.34355375CS
52-0.96-40.85106382982.354.210.85021937261.83242273CS
156-3.09-68.97321428574.487.380.85023427262.87700208CS
260-10.09-87.891986062711.4817.20.85022768253.26745561CS

LVTX - Frequently Asked Questions (FAQ)

What is the current LAVA Therapeutics NV share price?
The current share price of LAVA Therapeutics NV is US$ 1.39
How many LAVA Therapeutics NV shares are in issue?
LAVA Therapeutics NV has 26,289,087 shares in issue
What is the market cap of LAVA Therapeutics NV?
The market capitalisation of LAVA Therapeutics NV is USD 37.86M
What is the 1 year trading range for LAVA Therapeutics NV share price?
LAVA Therapeutics NV has traded in the range of US$ 0.8502 to US$ 4.21 during the past year
What is the PE ratio of LAVA Therapeutics NV?
The price to earnings ratio of LAVA Therapeutics NV is -0.88
What is the cash to sales ratio of LAVA Therapeutics NV?
The cash to sales ratio of LAVA Therapeutics NV is 5.44
What is the reporting currency for LAVA Therapeutics NV?
LAVA Therapeutics NV reports financial results in USD
What is the latest annual turnover for LAVA Therapeutics NV?
The latest annual turnover of LAVA Therapeutics NV is USD 6.77M
What is the latest annual profit for LAVA Therapeutics NV?
The latest annual profit of LAVA Therapeutics NV is USD -41.97M
What is the registered address of LAVA Therapeutics NV?
The registered address for LAVA Therapeutics NV is YALELAAN 62, UTRECHT, UTRECHT, 3584 CM
What is the LAVA Therapeutics NV website address?
The website address for LAVA Therapeutics NV is www.lavatherapeutics.com
Which industry sector does LAVA Therapeutics NV operate in?
LAVA Therapeutics NV operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CAPSCapstone Holding Corp
US$ 3.2211
(1,188.44%)
46.87k
STSSSharps Technology Inc
US$ 0.581
(95.82%)
251.99M
RDFNRedfin Corporation
US$ 9.905
(70.19%)
52.45M
SNOASonoma Pharmaceuticals Inc
US$ 3.3101
(66.34%)
23.85M
CKPTCheckpoint Therapeutics Inc
US$ 4.055
(64.17%)
28.85M
SXTCChina SXT Pharmaceuticals Inc
US$ 2.90
(-32.76%)
95.41k
ABLVAble View Global Inc
US$ 1.2467
(-28.35%)
479.29k
SUNESUNation Energy Inc
US$ 0.2952
(-25.92%)
9.97M
BTOGBit Origin Ltd
US$ 0.46
(-25.81%)
54.79M
MSTXTidal Trust II Defiance Daily Target 2x Long MSTR ETF
US$ 21.815
(-23.90%)
8.09M
STSSSharps Technology Inc
US$ 0.581
(95.82%)
251.99M
NVDANVIDIA Corporation
US$ 107.36
(-4.73%)
88.81M
ICONIcon Energy Corporation
US$ 0.14755
(-12.59%)
84.47M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 8.84
(-17.07%)
81.92M
SPRCSciSparc Ltd
US$ 0.3749
(17.30%)
81.9M

LVTX Discussion

View Posts
glenn1919 glenn1919 2 weeks ago
LVTX.................................https://stockcharts.com/h-sc/ui?s=LVTX&p=W&b=5&g=0&id=p86431144783
👍️0
subslover subslover 2 weeks ago
LAVA Announces Evaluation of Strategic Options
Advisor engaged in evaluating strategic options to maximize shareholder value

Cash balance of $76.6 million as of December 31, 2024

UTRECHT, The Netherlands and PHILADELPHIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, announced that the Company has initiated a process to review strategic options focused on maximizing shareholder value and has implemented cost curtailment including a workforce reduction. The Company has retained an experienced financial advisor to support LAVA with the strategic evaluation process. LAVA will continue to enroll in the Phase 1 clinical study evaluating the safety and pharmacokinetics of LAVA-1266 in hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and support its partnerships with Pfizer and Johnson and Johnson.

“While we will continue investigating LAVA-1266 in the potential treatment of AML and MDS and supporting our Gammabody pharma partnerships, with only one product in clinical development and an early-stage pipeline, we felt it appropriate to investigate strategic opportunities to drive additional shareholder value. LAVA is in a strong position to unlock strategic opportunities for the Company, in addition to our proprietary pipeline and partnered programs,” said Steve Hurly, Chief Executive Officer of LAVA.

The Company will explore and evaluate diverse strategic options to maximize shareholder value, including in-licensing of assets, a sale, licensing agreement, merger, acquisition, or other strategic transactions. There can be no assurance that this process will result in any such transaction. LAVA’s Board of Directors has not set a timetable for the strategic review process. LAVA does not intend to provide updates until the Board approves a specific action or otherwise determines that disclosure is appropriate or required.

In connection with the evaluation of strategic alternatives, LAVA is implementing a restructuring plan that includes a workforce reduction of approximately thirty percent, furthering cost-containment and cash conservation measures. The Company intends to retain all employees essential for supporting value creation as part of its strategic review. The Company estimates that it will incur approximately $0.5 million of one-time costs primarily incurred in Q1 2025 related to the workforce reduction.

“I want to express my sincere gratitude to each of our employees being affected by this workforce reduction,” said Mr. Hurly. “We thank them for their dedicated service and contribution to LAVA’s mission to advancing the portfolio of bispecific T cell engagers and our proprietary Gammabody platform.”

As of December 31, 2024, the Company’s cash, cash equivalents, and investments were $76.6 million (unaudited)
👍️0
glenn1919 glenn1919 5 months ago
LVTX..................https://stockcharts.com/h-sc/ui?s=LVTX&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 6 months ago
LVTX under $2
👍️0
Monksdream Monksdream 7 months ago
LVTX 10Q due AUGUST 19
👍️0
Dan88 Dan88 7 months ago
Quiet before storm!
👍️0
Monksdream Monksdream 8 months ago
LVTX under $3
👍️0
glenn1919 glenn1919 8 months ago
LVTX.............................https://stockcharts.com/h-sc/ui?s=LVTX&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 8 months ago
LVTX under $2
👍️0
PonkenPlonken PonkenPlonken 8 months ago
Pfizer could really use this compound and they are not making it a secret.
Its a falling knife as many others are right now but you are getting pennies on the dollar in my opinion.

Put in quite a bar in late February. Its because those in the know wanted shares.
👍️0
Monksdream Monksdream 10 months ago
Very little these days
👍️0
PonkenPlonken PonkenPlonken 10 months ago
The chart really has it all... Do you consider fundamentals?
👍️0
Monksdream Monksdream 10 months ago
Like the chart
👍️0
PonkenPlonken PonkenPlonken 11 months ago
PFE darling and pretty chart.
👍️0
Laster Laster 11 months ago
Looking to break $4 for good.
Consolidating at $3.90's.
Hope it's not going to be double top fail.
Time will tell.
👍️0
glenn1919 glenn1919 12 months ago
LVTX..............................https://stockcharts.com/h-sc/ui?s=LVTX&p=W&b=5&g=0&id=p86431144783
👍️0
Laster Laster 12 months ago
Excellent week.
Hopefully $4 next week.
👍️0
Laster Laster 12 months ago
Beautiful chart. Breakout past $3.30 to. $3.35.
Lots of cash.
Looking for at least $5 soon. Maybe more.
JMO.
👍️0
Monksdream Monksdream 12 months ago
LVTX 10Q due 3/22
👍️0
Laster Laster 12 months ago
Nice bounce back above $3.
Would love another run to $3.25.
I think this has good chance to move to $4 sooner or later. Lots of cash.
JMO
👍️0
Laster Laster 12 months ago
Crazy stock dropped on earnings news which means nothing IMO.
Typical sell on news. Stock will need to regroup before it can retest $3.
They have huge amounts of cash and good partners.
I am holding through this sell off.
👍️0
Laster Laster 12 months ago
Interesting. Trying to breakout.
Needs news.
👍️0
Laster Laster 12 months ago
Nice chart. They have cash to last until 2026.
Needs to breakout past $3 with volume.
Tried several times but failed.
👍️0
glenn1919 glenn1919 1 year ago
LVTX.........................................https://stockcharts.com/h-sc/ui?s=LVTX&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 1 year ago
LVTX.................................................https://stockcharts.com/h-sc/ui?s=LVTX&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 1 year ago
LVTX new 52 week high
👍️0
Stumblebum Stumblebum 1 year ago
Nice pump today sold some shares made a bundle ….weeeeeeeeeee
👍️0
kbaz kbaz 1 year ago
Insider and institutional ownership here are pretty big numbers. With the Merck partnership this should be heading North when the dip buying resolves..... This will soon be a battle ground between $3 and $4!
👍️0
kbaz kbaz 1 year ago
I hit this for a few more shares at 1.96 in Pre-market. I read some further and like the Merck Deal and that fact that they have the Balance Sheet Strength to partner with them!!!! Let's see how long I have to hold on to this, for it to Double from here!!!!
👍️0
Invest-in-America Invest-in-America 1 year ago
LVTX: I think we ALL eventually learned today this THIS ONE is a dud!!! (DAMN-IT!!!)
👍️0
power11 power11 1 year ago
WHAT DID I TEACH YOU LAST TIME : KNEEL AND OBEY YOUR MASTER !!
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
WATCH AND LEARN LOSER
👍️0
Invest-in-America Invest-in-America 1 year ago
LVTX: And there she goes!! (That MERCK name can do things, ya know.)

👍️0
Invest-in-America Invest-in-America 1 year ago
LVTX: The heck with those "SXTC-like", Chinese BAD-Fortune-Cookie routines!! Check-out the LVTX 'Bollinger-Curves' on MY cute 'Scanners'!! (See below!!)

"I suddenly feel a Short-SQUEEZE of sorts comin' on!! Can ya all help-me-out a little bit, Fellas??!!"
/////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
👍️0
power11 power11 1 year ago
OK SO NOW YOU'RE A MIND READER !! SIMPLY AMAZING !!
SO KEEP INVESTING IN THESE MICKEY MOUSE STOCKS, MAYBE ONE DAY THE LOTTO
IS IN YOUR FUTURE. ONE MORE REMINDER : ALWAYS LISSSSSSSSSSSSSSSSSSSSTEN TO YOUR MASTER !!
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
you own nothing...go back to work....you're lunch break is almost over
👍️0
power11 power11 1 year ago
THE MARKET SELL OFF I COMING VERY SOON. EVEN THOUGH I'M LONG, GOT PLENTY OF PROTECTION.
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
crown what happen to the market crash you keep telling people...stick to the trolling son...fake traders never lose!!!
👍️0
power11 power11 1 year ago
YOU MEAN THE MASTER TRADER OF ALL TIMES !!
OK SENIOR; VERY SIMPLE REALLY; STICK WITH MSFT, NVDA, AMZN GOOG, AND META.
DON'T OVRERTHINK IT.
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
coming from one of the great ihub traders i should listen to you...what are you buying these days big fella
👍️0
power11 power11 1 year ago
SELL !!
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
LVTX...COME ON YOU CAN DO IT
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
LVTX NEXT BIOP BEAST DAY TRADER
👍️0
Monksdream Monksdream 1 year ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
kbaz kbaz 1 year ago
Bought some Dip..... May pick up some more if the Morning Open get's a pullback...... Good one for a Move up into weekend!!!!!
👍️0
TheFinalCD TheFinalCD 1 year ago
LVTX 2.74= $$
👍️0
TheFinalCD TheFinalCD 1 year ago
$LVTX 2.44 I BOUGHT 1.92'S, YOU IN?
👍️0
TheFinalCD TheFinalCD 1 year ago
Cash Position The company has 28.7 months of cash left based on quarterly cash burn of -$9.62M and estimated current cash of $92.1M.
https://dilutiontracker.com/app/search/LVTX
👍️0
subslover subslover 1 year ago
Very nice find! Thank you so much! ")
👍️0
TheFinalCD TheFinalCD 1 year ago
$LVTX 1.89 NEWS Collaboration with Merck & Co $MRK

https://www.globenewswire.com/news-release/2024/01/25/2816550/0/en/LAVA-Therapeutics-Announces-Collaboration-with-Merck-Co-Inc-Rahway-NJ-USA-to-Evaluate-LAVA-1207-in-Combination-with-KEYTRUDA.html
👍️0

Your Recent History

Delayed Upgrade Clock